Diagnostic Center | April 04, 2024
Evonik unveils latest global trial results MetAMINO
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Cipla completes transfer of Generics Business Undertaking
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Subscribe To Our Newsletter & Stay Updated
